医学
炎症性肠病
内科学
炎症性肠病
溃疡性结肠炎
胃肠病学
梅德林
风险评估
肺病
疾病
克罗恩病
呼吸道疾病
风险因素
疾病严重程度
重症监护医学
克罗恩病
并发症
作者
Shaina Ailawadi,Trishna Parikh,Elleson Harper,Jaime Perez,Gregory S. Cooper,Preetika Sinh,Vu Nguyen,Jeffry Katz,Fabio Cominelli,Miguel Regueiro,Emad Mansoor
标识
DOI:10.1097/mcg.0000000000002327
摘要
BACKGROUND: Inflammatory bowel disease (IBD) is a multisystem illness with intestinal and extraintestinal manifestations. We aimed to analyze the association of developing pulmonary diseases (PDs) in patients with IBD. METHODS: In this retrospective cohort study, TriNetX was used to identify patients with IBD who were prescribed at least one IBD-specific medication or advanced therapy. Patients with an inpatient visit and no IBD comprised the control group. Propensity score matching (PSM) was used to balance cohorts. The odds ratio (OR) of developing PDs all-cause mortality were determined. RESULTS: After PSM, there were 155,668 patients (46.6±17.5 y, 50.9% female) in each group. Patients with IBD had an increased prevalence of developing all assessed PDs except for pyothorax (P=0.087), lung abscesses (P=0.411), pleural disease (OR: 0.89 [0.80-0.98], P=0.013), and pneumothorax (OR: 0.67 [0.62-0.73], P<0.001) compared with the control group. There were at least 2-fold increased prevalence of developing asthma (OR: 2.17 [2.09-2.26]), bronchiectasis (OR: 2.35 [2.12-2.61]), chronic bronchitis (OR: 2.40 [2.11-2.72]), and vasculitis (OR: 2.33 [1.99-2.72]) compared with the control group (all P<0.001). CONCLUSION: Given the increased association of developing PDs, clinicians should engage in proactive monitoring and risk reduction strategies to mitigate the development of various PDs in the IBD patient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI